TAILIEUCHUNG - Chapter 123. Clostridium difficile–Associated Disease, Including Pseudomembranous Colitis (Part 5)

Recurrent CDAD Overall, ~15–30% of patients experience recurrences of CDAD, either as relapses caused by the original organism or as reinfections following treatment (Table 123-2). Recurrence rates are higher among patients ≥65 years old and among patients who remain in the hospital after the initial episode of CDAD. Patients who have a first recurrence of CDAD have a high rate of second recurrence (33–65%). In the first recurrence, re-treatment with metronidazole is comparable to treatment with vancomycin. Recurrent disease, once thought to be relatively mild, has been documented to pose a significant (11%) risk of serious complications (shock, megacolon,. | Chapter 123. Clostridium difficile-Associated Disease Including Pseudomembranous Colitis Part 5 Recurrent CDAD Overall 15-30 of patients experience recurrences of CDAD either as relapses caused by the original organism or as reinfections following treatment Table 123-2 . Recurrence rates are higher among patients 65 years old and among patients who remain in the hospital after the initial episode of CDAD. Patients who have a first recurrence of CDAD have a high rate of second recurrence 33-65 . In the first recurrence re-treatment with metronidazole is comparable to treatment with vancomycin. Recurrent disease once thought to be relatively mild has been documented to pose a significant 11 risk of serious complications shock megacolon perforation colectomy or death within 30 days . There is no standard treatment for multiple recurrences but long or repeated metronidazole courses should be avoided because of potential neurotoxicity. Approaches include the administration of vancomycin followed by the yeast Saccharomyces boulardii the administration of vancomycin followed by synthetic fecal bacterial enema and the intentional colonization of the patient with a nontoxigenic strain of C. difficile. None of these biotherapeutic approaches has been approved by the FDA for use in the United States. Other strategies include 1 the use of vancomycin in tapering doses or with pulse dosing every other day for 4-6 weeks and 2 sequential treatment with vancomycin 125 mg four times daily followed by rifaximin 400 mg twice daily for 14 days. IV immunoglobulin which has also been used with some success presumably provides antibodies to C. difficile toxins. Fulminant CDAD Fulminant rapidly progressive and severe CDAD presents the most difficult treatment challenge. Patients with fulminant disease often do not have diarrhea and their illness mimics an acute surgical abdomen. Sepsis hypotension fever tachycardia leukocytosis may result from severe CDAD. An acute abdomen with or without

• Y học thường thức
• Clostridium difficile
• Associated Disease
• Including Pseudomembranous Colitis
• tài liệu y khoa
• Harrisons Internal Medicine
• Luận án Tiến sĩ Sinh học
• Vi sinh vật học
• Dịch tễ học phân tử
• Clostridium difficile mang gen độc tố
• Vi khuẩn Clostridium difficile
• Nuôi cấy phân lập Clostridium difficile
• Trung hòa độc tố tế bào
• Tạp chí Y học
• Bài viết về y học
• Tiêu chảy cấp nặng
• Tiêu chảy do Clostridium difficile
• Vancomycin đường uống
• BMC Pharmacology and Toxicology
• Clostridium difficile associated diarrhea
• Clostridium difficile infection
• Lipopeptide antibacterial
• BMC Pediatrics
• Colonic stenosis
• Antibiotic related Clostridium difficile colitis
• Barium enema
• Summary of Phd thesis on Medicine
• Risk factors of the diarrhea caused
• Diarrhea caused by clostridium difficile
• Adults at Bach Mai hospital
• Clostridium difficile toxins production
• Optimal conditions
• Vaccine production
• Incubation period
• Molecular epidemiology
• Identify toxigenic
• Non toxigenic C
• Clostridium difficile tcdA
• Toxins immunogenic potential in mice
• Immunogenic potential in mice
• Culture supernatants
• Luận án Tiến sĩ
• Luận án Tiến sĩ Y học
• Đặc điểm dịch tễ bệnh tiêu chảy
• Nguy cơ mắc tiêu chảy do Clostridium Difficile
• Master's thesis of Applied Science
• Master's thesis
• Ribotype 027 hypervirulent strains
• HRM and ScreenClust
• North American pulsed field type
• Health care–associated diarrhea
• Polymerase chain reaction
• Tóm tắt luận án Tiến sĩ
• Tóm tắt luận án Tiến sĩ Y học
• Bệnh tiêu chảy ở người lớn
• Dự thảo tóm tắt Luận án Tiến sĩ
• Đặc điểm dịch tễ học phân tử
• BMC Anesthesiology
• Intensive care
• Cardiac surgery
• High risk
• Critical care
• Adverse drug events
• Antimicrobial stewardship
• Prior meta analyses
• CDI epidemiology
• Giáo dục đào tạo
• Giáo trình
• Giáo án
• Bài giảng
• Y học
• Tài liệu
• Đề cương
• trình bày báo cáo
• tài liệu báo cáo khoa học
• báo cáo y học
• kiến thức y học
• nghiên cứu y học
• medical books
• pharmacology
• epidemiologic
• Obstetrics
• anatomy
• Preventing Morbidity
• Multidisciplinary Care
• statements and documents scientific reports
• medical reports
• medical knowledge
• medical research
• Báo cáo khoa học
• công trình nghiên cứu về y học
• tài liệu về y học
• cách trình bày báo cáo